## Evofem Biosciences to Report Fourth Quarter and Yearend 2018 Results and Provide Corporate Update on March 1, 2019

-- Conference Call Scheduled for 11:00 a.m. EST --

SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2018, as follows:

| Date                        | Friday March 1, 2019   |
|-----------------------------|--|
| Time                        | 11:00 a.m. EST   |
| Dial-in numbers             | (866) 503-5561 (U.S. toll-free) or (253) 336-2965              |
| Passcode                    | 5892398  |
| Webcast (live and archived) | www.evofem.com under " <u>Investors</u> " or <u>click here</u> |

The teleconference replay will be available approximately two hours after completion through Wednesday, March 6, 2019, at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The replay access code is 5892398. The archived webcast will be available via the aforementioned URLs.

## **About Evofem Biosciences**

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs). The Company is leveraging its proprietary Multi-purpose Vaginal pH Regulator™ (MVP-R) platform to develop Amphora which, if approved, will be the first on-demand and female controlled MVP-R birth control method in the U.S. For more information regarding Evofem, please visit www.evofem.com.

Amphora® is a registered trademark and Multipurpose Vaginal pH Regulator™ is a trademark of Evofem Biosciences, Inc.

## Contact

Amy Raskopf Evofem Biosciences, Inc. araskopf@evofem.com C: (917) 673-5775

O: (858) 550-1900 x167

SOURCE Evofem Biosciences, Inc.